Bayer closes $14.2 bn deal to acquire Merck's consumer care business
With this Bayer becomes one of the leading players in the global OTC (over-the-counter) market
BS B2B Bureau B2B Connect | Leverkusen, Germany
Bayer paid a purchase price of $ 14.2 billion, less certain contingent amounts held back that will be payable upon antitrust approvals in Mexico and the Republic of Korea. Integration of the acquired business has been successfully initiated. The combined consumer care business is headed by Erica Mann, member of the Bayer HealthCare Executive Committee and responsible for the Consumer Care division.
The acquisition significantly enhances Bayer's over-the-counter (OTC) business across multiple therapeutic categories and geographies. Pro forma sales of the combined businesses in 2013 amounted to $ 7.4 billion (Euro 5.5 billion), with Merck & Co’s business contributing approximately $ 2.2 billion. The acquisition will give Bayer the global number two position in non-prescription medication - behind the combined OTC businesses of Novartis and GlaxoSmithKline, following the completion of their announced joint venture in 2015, and ahead of the world's previous industry leader Johnson & Johnson.
More From This Section
The consumer care business acquired from Merck & Co is primarily comprised of products in the cold, allergy, sinus & flu; dermatology (including sun care); foot health; and gastrointestinal categories.
Also Read
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Oct 04 2014 | 11:35 AM IST